SMPD3 and cancer: Currently, although GW4869 and Nexinhib-20 are drugs targeting key enzymes NSMASE2 and RAB27A in the exosome, restraining exosomal releases in various cancer cell lines, such as PC3 and MC38, proves difficult (97–99).